OA12431A - Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. - Google Patents

Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. Download PDF

Info

Publication number: OA12431A
Authority: OA; OAPI
Prior art keywords: oxidized; médicament; proteins; binding; protein
Prior art date: 2000-10-20

Application number

OA1200300119A

Other languages

English (en)

Inventor

Beate Kehrel

Martin Brodde

Original Assignee

Beate Kehrel

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-20

Filing date

2001-10-19

Publication date

2006-04-19

2000-10-20 Priority claimed from DE10051983A external-priority patent/DE10051983A1/de

2001-10-02 Priority claimed from DE2001148624 external-priority patent/DE10148624A1/de

2001-10-19 Application filed by Beate Kehrel filed Critical Beate Kehrel

2006-04-19 Publication of OA12431A publication Critical patent/OA12431A/en

Links

102000004169 proteins and genes Human genes 0.000 title claims abstract description 167
108090000623 proteins and genes Proteins 0.000 title claims abstract description 167
230000005764 inhibitory process Effects 0.000 title claims description 21
230000007246 mechanism Effects 0.000 title description 3
230000004071 biological effect Effects 0.000 title description 2
230000001225 therapeutic effect Effects 0.000 title description 2
108010045374 CD36 Antigens Proteins 0.000 claims abstract description 153
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 42
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
230000006870 function Effects 0.000 claims abstract description 8
239000003146 anticoagulant agent Substances 0.000 claims abstract description 4
102000049320 CD36 Human genes 0.000 claims abstract 19
102100036034 Thrombospondin-1 Human genes 0.000 claims description 50
102000002938 Thrombospondin Human genes 0.000 claims description 36
108060008245 Thrombospondin Proteins 0.000 claims description 36
108010049003 Fibrinogen Proteins 0.000 claims description 30
102000008946 Fibrinogen Human genes 0.000 claims description 30
102000008100 Human Serum Albumin Human genes 0.000 claims description 30
108091006905 Human Serum Albumin Proteins 0.000 claims description 30
229940012952 fibrinogen Drugs 0.000 claims description 30
238000000034 method Methods 0.000 claims description 24
239000000126 substance Substances 0.000 claims description 20
206010003210 Arteriosclerosis Diseases 0.000 claims description 16
208000011775 arteriosclerosis disease Diseases 0.000 claims description 16
230000001404 mediated effect Effects 0.000 claims description 16
230000003993 interaction Effects 0.000 claims description 15
201000010099 disease Diseases 0.000 claims description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
230000004054 inflammatory process Effects 0.000 claims description 12
102000005962 receptors Human genes 0.000 claims description 12
108020003175 receptors Proteins 0.000 claims description 12
101710159964 Tail sheath protein Proteins 0.000 claims description 10
101710168563 Tail spike protein Proteins 0.000 claims description 10
238000002560 therapeutic procedure Methods 0.000 claims description 10
208000031886 HIV Infections Diseases 0.000 claims description 9
206010061218 Inflammation Diseases 0.000 claims description 9
238000011161 development Methods 0.000 claims description 9
108700024827 HOC1 Proteins 0.000 claims description 8
101100178273 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HOC1 gene Proteins 0.000 claims description 8
206010063837 Reperfusion injury Diseases 0.000 claims description 7
208000015181 infectious disease Diseases 0.000 claims description 7
206010028980 Neoplasm Diseases 0.000 claims description 6
230000033115 angiogenesis Effects 0.000 claims description 6
KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 claims description 5
206010018364 Glomerulonephritis Diseases 0.000 claims description 5
208000037357 HIV infectious disease Diseases 0.000 claims description 5
206010020772 Hypertension Diseases 0.000 claims description 5
208000007536 Thrombosis Diseases 0.000 claims description 5
230000006378 damage Effects 0.000 claims description 5
230000023597 hemostasis Effects 0.000 claims description 5
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 5
230000006698 induction Effects 0.000 claims description 5
238000011002 quantification Methods 0.000 claims description 5
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
208000024869 Goodpasture syndrome Diseases 0.000 claims description 4
208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
241000282412 Homo Species 0.000 claims description 4
201000009053 Neurodermatitis Diseases 0.000 claims description 4
241000721454 Pemphigus Species 0.000 claims description 4
108090000783 Renin Proteins 0.000 claims description 4
102100028255 Renin Human genes 0.000 claims description 4
206010040047 Sepsis Diseases 0.000 claims description 4
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
206010009887 colitis Diseases 0.000 claims description 4
206010012601 diabetes mellitus Diseases 0.000 claims description 4
238000007912 intraperitoneal administration Methods 0.000 claims description 4
208000017169 kidney disease Diseases 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
230000014399 negative regulation of angiogenesis Effects 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
201000003068 rheumatic fever Diseases 0.000 claims description 4
238000001356 surgical procedure Methods 0.000 claims description 4
230000001154 acute effect Effects 0.000 claims description 3
239000010836 blood and blood product Substances 0.000 claims description 3
208000015294 blood coagulation disease Diseases 0.000 claims description 3
229940125691 blood product Drugs 0.000 claims description 3
238000012544 monitoring process Methods 0.000 claims description 3
210000000056 organ Anatomy 0.000 claims description 3
238000002054 transplantation Methods 0.000 claims description 3
238000011282 treatment Methods 0.000 claims description 3
208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
230000002785 anti-thrombosis Effects 0.000 claims description 2
229940088710 antibiotic agent Drugs 0.000 claims description 2
230000010100 anticoagulation Effects 0.000 claims description 2
230000003143 atherosclerotic effect Effects 0.000 claims description 2
238000012512 characterization method Methods 0.000 claims description 2
230000001684 chronic effect Effects 0.000 claims description 2
238000003745 diagnosis Methods 0.000 claims description 2
229960003444 immunosuppressant agent Drugs 0.000 claims description 2
239000003018 immunosuppressive agent Substances 0.000 claims description 2
238000007918 intramuscular administration Methods 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims description 2
208000031225 myocardial ischemia Diseases 0.000 claims description 2
238000002823 phage display Methods 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
230000026731 phosphorylation Effects 0.000 claims description 2
238000006366 phosphorylation reaction Methods 0.000 claims description 2
238000003908 quality control method Methods 0.000 claims description 2
208000037803 restenosis Diseases 0.000 claims description 2
230000005747 tumor angiogenesis Effects 0.000 claims description 2
230000029663 wound healing Effects 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 3
239000000427 antigen Substances 0.000 claims 1
102000036639 antigens Human genes 0.000 claims 1
108091007433 antigens Proteins 0.000 claims 1
230000000699 topical effect Effects 0.000 claims 1
238000006243 chemical reaction Methods 0.000 abstract description 27
230000000694 effects Effects 0.000 abstract description 15
QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 abstract description 3
239000000556 agonist Substances 0.000 abstract description 2
239000003795 chemical substances by application Substances 0.000 abstract description 2
208000001953 Hypotension Diseases 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000002456 anti-arthritic effect Effects 0.000 abstract 1
230000000844 anti-bacterial effect Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000036436 anti-hiv Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000003356 anti-rheumatic effect Effects 0.000 abstract 1
230000000767 anti-ulcer Effects 0.000 abstract 1
229940127219 anticoagulant drug Drugs 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
239000003435 antirheumatic agent Substances 0.000 abstract 1
230000001966 cerebroprotective effect Effects 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
208000021822 hypotensive Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000002537 thrombolytic effect Effects 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 146
102000053028 CD36 Antigens Human genes 0.000 description 134
210000001772 blood platelet Anatomy 0.000 description 96
210000004027 cell Anatomy 0.000 description 56
108090000935 Antithrombin III Proteins 0.000 description 48
102000004411 Antithrombin III Human genes 0.000 description 41
229960005348 antithrombin iii Drugs 0.000 description 41
108010046722 Thrombospondin 1 Proteins 0.000 description 39
210000002540 macrophage Anatomy 0.000 description 27
210000001616 monocyte Anatomy 0.000 description 24
241000699670 Mus sp. Species 0.000 description 21
230000004913 activation Effects 0.000 description 20
230000015572 biosynthetic process Effects 0.000 description 16
239000000872 buffer Substances 0.000 description 16
238000002474 experimental method Methods 0.000 description 13
230000008569 process Effects 0.000 description 13
108010071584 oxidized low density lipoprotein Proteins 0.000 description 11
108010007622 LDL Lipoproteins Proteins 0.000 description 10
102000007330 LDL Lipoproteins Human genes 0.000 description 10
230000003647 oxidation Effects 0.000 description 10
238000007254 oxidation reaction Methods 0.000 description 10
238000002965 ELISA Methods 0.000 description 9
230000002776 aggregation Effects 0.000 description 9
238000004220 aggregation Methods 0.000 description 9
150000002632 lipids Chemical class 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
102100022977 Antithrombin-III Human genes 0.000 description 8
238000004113 cell culture Methods 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
239000011859 microparticle Substances 0.000 description 8
108010035532 Collagen Proteins 0.000 description 7
102000008186 Collagen Human genes 0.000 description 7
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 7
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 7
230000000903 blocking effect Effects 0.000 description 7
229920001436 collagen Polymers 0.000 description 7
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
208000000104 Arthus reaction Diseases 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
206010053614 Type III immune complex mediated reaction Diseases 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000012528 membrane Substances 0.000 description 6
210000002381 plasma Anatomy 0.000 description 6
230000019254 respiratory burst Effects 0.000 description 6
210000000329 smooth muscle myocyte Anatomy 0.000 description 6
102000012422 Collagen Type I Human genes 0.000 description 5
108010022452 Collagen Type I Proteins 0.000 description 5
102000009109 Fc receptors Human genes 0.000 description 5
108010087819 Fc receptors Proteins 0.000 description 5
102000003896 Myeloperoxidases Human genes 0.000 description 5
108090000235 Myeloperoxidases Proteins 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
229940096422 collagen type i Drugs 0.000 description 5
238000004163 cytometry Methods 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
210000004623 platelet-rich plasma Anatomy 0.000 description 5
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
108010046315 IDL Lipoproteins Proteins 0.000 description 4
210000000497 foam cell Anatomy 0.000 description 4
230000002439 hemostatic effect Effects 0.000 description 4
238000002955 isolation Methods 0.000 description 4
150000004668 long chain fatty acids Chemical class 0.000 description 4
201000004792 malaria Diseases 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000004005 microsphere Substances 0.000 description 4
230000005012 migration Effects 0.000 description 4
238000013508 migration Methods 0.000 description 4
230000001590 oxidative effect Effects 0.000 description 4
210000004303 peritoneum Anatomy 0.000 description 4
150000003904 phospholipids Chemical class 0.000 description 4
230000003331 prothrombotic effect Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
108090000672 Annexin A5 Proteins 0.000 description 3
102000004121 Annexin A5 Human genes 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
206010030113 Oedema Diseases 0.000 description 3
102100031574 Platelet glycoprotein 4 Human genes 0.000 description 3
101710202087 Platelet glycoprotein 4 Proteins 0.000 description 3
-1 QH-radicals Chemical compound 0.000 description 3
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
239000004473 Threonine Substances 0.000 description 3
108090000190 Thrombin Proteins 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
241000700605 Viruses Species 0.000 description 3
210000000709 aorta Anatomy 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000001364 causal effect Effects 0.000 description 3
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000010494 dissociation reaction Methods 0.000 description 3
230000005593 dissociations Effects 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
239000007800 oxidant agent Substances 0.000 description 3
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
210000001539 phagocyte Anatomy 0.000 description 3
239000013641 positive control Substances 0.000 description 3
230000000284 resting effect Effects 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
229960004072 thrombin Drugs 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
238000005406 washing Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
102000013918 Apolipoproteins E Human genes 0.000 description 2
108010025628 Apolipoproteins E Proteins 0.000 description 2
102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
102100037904 CD9 antigen Human genes 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108010014172 Factor V Proteins 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241000224016 Plasmodium Species 0.000 description 2
206010038563 Reocclusion Diseases 0.000 description 2
108091005487 SCARB1 Proteins 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
210000001789 adipocyte Anatomy 0.000 description 2
230000032683 aging Effects 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
239000004019 antithrombin Substances 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
230000008033 biological extinction Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000007123 defense Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
230000004927 fusion Effects 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
238000005259 measurement Methods 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
238000005502 peroxidation Methods 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
238000011533 pre-incubation Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
230000009145 protein modification Effects 0.000 description 2
238000005096 rolling process Methods 0.000 description 2
238000009738 saturating Methods 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
239000002356 single layer Substances 0.000 description 2
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000032258 transport Effects 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
229960005508 8-azaguanine Drugs 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
101150112561 CD36 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000050079 Class B Scavenger Receptors Human genes 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
102000001187 Collagen Type III Human genes 0.000 description 1
108010069502 Collagen Type III Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
206010014025 Ear swelling Diseases 0.000 description 1
101710126486 Envelope glycoprotein D Proteins 0.000 description 1
101710126496 Envelope glycoprotein I Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
108010074105 Factor Va Proteins 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000006481 HIV Receptors Human genes 0.000 description 1
108010083930 HIV Receptors Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
102000002268 Hexosaminidases Human genes 0.000 description 1
108010000540 Hexosaminidases Proteins 0.000 description 1
101000757319 Homo sapiens Antithrombin-III Proteins 0.000 description 1
101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 1
206010053317 Hydrophobia Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
229910019093 NaOCl Inorganic materials 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
101150001535 SRC gene Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
239000005708 Sodium hypochlorite Substances 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
102000012607 Thrombomodulin Human genes 0.000 description 1
108010079274 Thrombomodulin Proteins 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
229920004929 Triton X-114 Polymers 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003302 anti-idiotype Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
229950011321 azaserine Drugs 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
125000005340 bisphosphate group Chemical group 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
238000004891 communication Methods 0.000 description 1
239000010949 copper Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000002498 deadly effect Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
102000013574 human thrombospondin-1 Human genes 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000008604 lipoprotein metabolism Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
108010071421 milk fat globule Proteins 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000026762 natural killer cell apoptotic process Effects 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
ABCVHPIKBGRCJA-UHFFFAOYSA-N nonyl 8-[(8-heptadecan-9-yloxy-8-oxooctyl)-(2-hydroxyethyl)amino]octanoate Chemical compound OCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCCCCC(=O)OCCCCCCCCC ABCVHPIKBGRCJA-UHFFFAOYSA-N 0.000 description 1
235000021590 normal diet Nutrition 0.000 description 1
210000003924 normoblast Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000003024 peritoneal macrophage Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
206010034754 petechiae Diseases 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
230000002399 phagocytotic effect Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
239000003805 procoagulant Substances 0.000 description 1
230000006318 protein oxidation Effects 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000036647 reaction Effects 0.000 description 1
231100000272 reduced body weight Toxicity 0.000 description 1
239000012146 running buffer Substances 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
108091005484 scavenger receptor class B Proteins 0.000 description 1
102000014452 scavenger receptors Human genes 0.000 description 1
108010078070 scavenger receptors Proteins 0.000 description 1
210000003291 sinus of valsalva Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
108700026239 src Genes Proteins 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000012536 storage buffer Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940071127 thioglycolate Drugs 0.000 description 1
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
238000007395 thrombosis prophylaxis Methods 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Virology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Oncology (AREA)
Marine Sciences & Fisheries (AREA)
Zoology (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)

OA1200300119A 2000-10-20 2001-10-19 Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. OA12431A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10051983A DE10051983A1 (de)	2000-10-20	2000-10-20	Inhibierung der pathogenen Wirkung oxidierter Proteine
DE2001148624 DE10148624A1 (de)	2001-10-02	2001-10-02	Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten

Publications (1)

Publication Number	Publication Date
OA12431A true OA12431A (en)	2006-04-19

Family

ID=26007431

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200300119A OA12431A (en)	2000-10-20	2001-10-19	Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.

Country Status (13)

Country	Link
EP (2)	EP1994941A3 (da)
JP (1)	JP4881535B2 (da)
AP (2)	AP2781A (da)
AT (1)	ATE406908T1 (da)
AU (1)	AU2002215032A1 (da)
CA (1)	CA2453140C (da)
CY (1)	CY1110418T1 (da)
DE (1)	DE50114289D1 (da)
DK (1)	DK1328289T3 (da)
ES (1)	ES2307662T3 (da)
OA (1)	OA12431A (da)
PT (1)	PT1328289E (da)
WO (1)	WO2002032445A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2375601T3 (es) *	2003-04-25	2012-03-02	Hamburger Stiftung Zur Förderung Von Wissenschaft Und Kultur	Lucha contra infecciones por virus de ih con plasma sangu�?neo humano oxidado con �?cido hipocloroso.
KR20140042940A (ko) *	2005-09-16	2014-04-07	코넬 리서치 화운데이션,인크.	Ｃｄ36 발현을 감소시키는 방법
JP2010235447A (ja) *	2007-07-30	2010-10-21	Igaku Seibutsugaku Kenkyusho:Kk	炎症性サイトカインの抑制剤
DE102010043733A1 (de)	2010-11-10	2012-05-10	Oxprotect Gmbh	Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
DE102011003936A1 (de)	2011-02-10	2012-08-16	Oxprotect Gmbh	Verwendung von Proteinen/Peptiden, welche an GRP78 (BIP) binden, in Labormethoden zum Monitoring von Thrombozyten-Aggregationshemmern
DE102011003944A1 (de)	2011-02-10	2012-08-16	Oxprotect Gmbh	Detektion und Entfernung von missgefalteten Proteinen/Peptiden
US10531655B2 (en)	2011-12-02	2020-01-14	The Regents Of The University Of California	Reperfusion protection solution and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3819923A1 (de) *	1988-06-11	1989-12-21	Behringwerke Ag	Fibrin(ogen)derivate, verfahren zu ihrer herstellung und ihre verwendung
US5192264A (en) *	1989-10-06	1993-03-09	The Beth Israel Hospital Association	Methods and apparatus for treating disease states using oxidized lipoproteins
AU7040091A (en) *	1989-10-06	1991-04-28	Beth Israel Hospital Association, The	Methods and apparatus for treating disease states using oxidized lipoproteins
CA2072587A1 (en) *	1990-01-08	1991-07-09	Gail F. Seelig	Oxidized variants of gm-csf
CA2086921A1 (en) *	1990-07-18	1992-01-19	Eric T. Fossel	Method for treating viral infections using oxidized lipoproteins
NZ275054A (en)	1993-11-08	1997-04-24	Peptide Delivery Systems Pty L	Diagnosing atherosclerosis or coronary artery disease using labelled composition which mimics essential features of an exogenous lipoprotein
RU2089179C1 (ru) *	1995-12-14	1997-09-10	Закрытое акционерное общество "ВАМ"	Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
CA2294355C (en)	1997-06-20	2006-11-28	Leuven Research & Development Vzw	Assays, antibodies, and standards for detection of oxidized and mda-modified low density lipoproteins
GB9806632D0 (en) *	1998-03-28	1998-05-27	Stevenson Robert	Peptide factor
EP1124985A4 (en) *	1998-11-06	2003-01-15	Univ Emory	BIOMARKER FOR OXIDATIVE STRESS
DE10045047A1 (de) *	2000-09-12	2002-03-21	Beate Kehrel	Arzneimittel enthaltend aktiviertes Antithrombin III

2001
- 2001-10-19 AU AU2002215032A patent/AU2002215032A1/en not_active Abandoned
- 2001-10-19 EP EP08012302A patent/EP1994941A3/de not_active Withdrawn
- 2001-10-19 AP AP2009004857A patent/AP2781A/xx active
- 2001-10-19 JP JP2002535683A patent/JP4881535B2/ja not_active Expired - Fee Related
- 2001-10-19 EP EP01983562A patent/EP1328289B1/de not_active Expired - Lifetime
- 2001-10-19 AP APAP/P/2003/002795A patent/AP2034A/en active
- 2001-10-19 OA OA1200300119A patent/OA12431A/en unknown
- 2001-10-19 CA CA2453140A patent/CA2453140C/en not_active Expired - Fee Related
- 2001-10-19 AT AT01983562T patent/ATE406908T1/de active
- 2001-10-19 WO PCT/EP2001/012129 patent/WO2002032445A2/de not_active Ceased
- 2001-10-19 DE DE50114289T patent/DE50114289D1/de not_active Expired - Lifetime
- 2001-10-19 DK DK01983562T patent/DK1328289T3/da active
- 2001-10-19 PT PT01983562T patent/PT1328289E/pt unknown
- 2001-10-19 ES ES01983562T patent/ES2307662T3/es not_active Expired - Lifetime
2008
- 2008-11-19 CY CY20081101332T patent/CY1110418T1/el unknown

Also Published As

Publication number	Publication date
PT1328289E (pt)	2008-12-10
ES2307662T3 (es)	2008-12-01
WO2002032445A2 (de)	2002-04-25
DK1328289T3 (da)	2008-12-15
EP1328289B1 (de)	2008-09-03
AP2781A (en)	2013-10-31
AP2009004857A0 (en)	2009-06-30
ATE406908T1 (de)	2008-09-15
JP4881535B2 (ja)	2012-02-22
AU2002215032A1 (en)	2002-04-29
CA2453140A1 (en)	2002-04-25
AP2034A (en)	2009-08-28
WO2002032445A3 (de)	2003-04-17
CY1110418T1 (el)	2015-04-29
JP2004511526A (ja)	2004-04-15
EP1994941A2 (de)	2008-11-26
HK1057857A1 (en)	2004-04-23
EP1328289A2 (de)	2003-07-23
AP2003002795A0 (en)	2003-06-30
EP1994941A3 (de)	2012-07-25
DE50114289D1 (de)	2008-10-16
CA2453140C (en)	2016-01-05

Publication	Publication Date	Title
CN1254275C (zh)	2006-05-03	抗血栓药剂和抗维勒布兰德因子单克隆抗体
HUP0200353A2 (hu)	2002-05-29	Fehérje, vérlemezkék tapadásának gátlására
US7273925B1 (en)	2007-09-25	Methods and products for regulating lectin complement pathway associated complement activation
Lima et al.	2019	From patients to platelets and back again: pharmacological approaches to glycoprotein VI, a thrilling antithrombotic target with minor bleeding risks
EP1140171A1 (en)	2001-10-10	Methods and products for regulating lectin complement pathway associated complement activation
PL204449B1 (pl)	2010-01-29	DNA kodujący glikoproteinę VI
US8034769B2 (en)	2011-10-11	Oxidized proteins and oxidized protein inhibitor compositions and methods of use thereof
CA2453140C (en)	2016-01-05	Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins and from the inhibition thereof
KR20010102130A (ko)	2001-11-15	지혈 및 면역기능에 사용하기 위한 억제제
US20110236455A1 (en)	2011-09-29	Novel Regulators of the Innate Immune System
WO2007011682A2 (en)	2007-01-25	Methods and reagents for screening new drugs and for treating ion pump associated disorders and diseases
JP2006516024A (ja)	2006-06-15	α１β１インテグリンの誘導性リガンドおよび使用
US7223730B2 (en)	2007-05-29	Antithrombosis enzyme from the snake venom of agkistrodon acutus
DE10148624A1 (de)	2003-04-10	Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten
WO1998016548A1 (en)	1998-04-23	Thrombin receptor peptides and uses thereof
WO2016021894A1 (ko)	2016-02-11	Ｃｄ９ 항체를 유효성분으로 함유하는 세포노화 또는 노화 관련 질환 예방 또는 치료용 약학조성물
HK1057857B (en)	2009-04-24	Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
O'Sullivan	2021	An investigation of the role of ACTN1 in platelet formation and of platelet function in myeloma
HK1121392A (en)	2009-04-24	Medicine containing at least one oxidised protein
Lo	2019	Investigating the functional roles of NBEAL2 in megakaryocytes and platelets
Visconte	2018	Roles of Amyloid Precursor Protein in Platelet Function
Szewczyk	2011	BIOTECHNOLOGICAL INVENTION OF CALOXINS-A NOVEL CLASS OF ALLOSTERIC INHIBITORS SPECIFIC FOR PLASMA MEMBRANE CALCIUM PUMP ISOFORMS
RA	2007	Impaired platelet function in a patient with P2Y, deficiency caused by a mutation in the translation initiation codon
FR2895262A1 (fr)	2007-06-29	Inhibition de la reponse immunitaire anti-fviii
Acquasaliente	2014	Coagulation protein factors: discovering novel interactions of thrombin